SEC Form 4 · accession 0001140361-17-033210
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles N York II
Officer — Chief Financial Officer and VP
Period of report
Aug 22, 2017
Accepted (ET)
Aug 24, 2017 · 6:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.10 | Aug 22, 2017 | A | 58,500 | A | — | Aug 21, 2027 | Common Stock | 58,500 | 58,500 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date.